[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100296966":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":34,"responsibleParty":63,"collaborators":32,"id":65,"slug":32,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":32,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":32,"enrollmentInfo":73,"targetDuration":32,"studyType":76,"phases":77,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":37,"whyStopped":32,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"AHS Cancer Control Alberta","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"[68]Ga-HA-DOTATATE","EXPERIMENTAL","All participants will be imaged with \\[68\\]Ga-HA-DOTATATE PET\u002FCT or PET\u002FMRI for uptake by somatostatin receptor positive tumours. Up to seven \\[68\\]Ga-HA-DOTATATE scans may be performed per participant, as clinically indicated.",[13],"Drug: [68]Ga-HA-DOTATATE",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","All participants will be injected with \\[68\\]Ga-HA-DOTATATE approximately 60 minutes before PET\u002FCT or PET\u002FMRI scan.",[9],[20,21],"Gallium-68 high affinity-DOTATATE","Gallium-68 DOTA-3-iodo-Tyr(3)-octreotate",[23],{"name":24,"affiliation":25,"role":26},"Todd PW McMullen, MD, PhD, FRCSC, FACS","Associate Professor of Surgery and Oncology; Director, Division of Surgical Oncology, Department of Oncology","PRINCIPAL_INVESTIGATOR",[28],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"NET Coordinator","CONTACT","780-577-8080",null,"ACB.NeuroEndocrine@ahs.ca",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Cross Cancer Institute","RECRUITING","Edmonton","Alberta","T6G 1Z2","Canada","CA",{"type":44,"coordinates":45},"Point",[46,47],-113.46871,53.55014,{"lat":47,"lon":46},[50,53,55,57,59,61],{"name":51,"role":52,"phone":32,"phoneExt":32,"email":32},"Stella Koumna, MD","SUB_INVESTIGATOR",{"name":54,"role":52,"phone":32,"phoneExt":32,"email":32},"Daniel Thut, MD",{"name":56,"role":52,"phone":32,"phoneExt":32,"email":32},"Donald W Morrish, MD, PhD, FRCPC",{"name":58,"role":52,"phone":32,"phoneExt":32,"email":32},"Jonathan Porter, MD",{"name":60,"role":52,"phone":32,"phoneExt":32,"email":32},"Freimut Juengling, MD",{"name":62,"role":52,"phone":32,"phoneExt":32,"email":32},"Omar Abdelsalam, MD",{"type":64,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100296966",false,"NCT03145857","A Study to Evaluate a New Way to Identify\u002FDiagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use","A Phase I\u002FII Study of Gallium-68 HA-DOTATATE ([68]Ga-HA-DOTATATE) in Patients With Known or Suspected Somatostatin Receptor Positive Tumours","Inclusion Criteria:\n\n1. Known or suspected somatostatin receptor positive tumour including, but not limited to, GNET, PNET, pulmonary NET, PRUNK NET, pheochromocytoma, paraganglioma, medullary thyroid cancer, and medulloblastoma. A standard CT obtained within 6 months of enrolment is required. A standard MRI obtained within 6 months of enrolment is optional. Additional supporting evidence obtained within 12 months of enrolment may include: other standard imaging (In-111 octreotide (Octreoscan), \\[18\\]F-FDG PET, or \\[18\\]F-FDOPA PET); histopathology from surgery or biopsy; elevated biochemical markers (including Chromogranin A, 5-HIAA, insulin, vasoactive intestinal peptide (VIP), glucagon, gastrin, metanephrines, and\u002For others, as clinically indicated); and\u002For persistent carcinoid-like symptomology highly suspicious for the presence of NET even in absence of pathologic imaging findings by anatomic criteria;\n2. Eastern Cooperative Oncology Group (ECOG) Performance Scale Score ≤ 3 within 2 weeks of enrolment;\n3. At least 14 years of age;\n4. Able and willing to follow instructions and comply with the protocol;\n5. Ability to provide written informed consent prior to participation in the study.\n\nExclusion Criteria:\n\n1. Inability to lie still for the entire imaging time (e.g. cough, severe arthritis, etc.);\n2. Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.);\n3. Any additional medical condition, serious inter-current illness or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study performance or interpretation;\n4. Weight exceeding the PET\u002FCT or PET\u002FMR scanner limit;\n5. Pregnancy;\n6. Allergic reaction to DOTATATE or somatostatin analogues.","ALL","14 Years",{"count":74,"type":75},1534,"ESTIMATED","INTERVENTIONAL",[78,79],"PHASE1","PHASE2","A \\[68\\]Ga-HA-DOTATATE PET\u002FCT or PET\u002FMRI scan is a nuclear medicine test used to create pictures of the whole body that will show where somatostatin receptors are found, including on tumours. Somatostatin receptors are found on most neuroendocrine tumours (NETs), and some other types of tumours. Currently at the Cross Cancer Institute, most patients with suspected somatostatin positive tumours (e.g. NETs) have an In-111 Octreotide (Octreoscan™) scan. A scientific study has shown that a scan with a similar product (\\[68\\]Ga-DOTATATE) is more accurate than an Octreoscan™. This study will look at \\[68\\]Ga-HA-DOTATATE, a product virtually identical to \\[68\\]Ga-DOTATATE.\n\nThe purpose of this study is to: 1) demonstrate the safety of \\[68\\]Ga-HA-DOTATATE; and 2) confirm that \\[68\\]Ga-HA-DOTATATE PET\u002FCT or PET\u002FMRI is effective at diagnosing somatostatin positive tumours.",[82],"Neuroendocrine Tumors",[84,85,86],"Gallium-68","Positron Emission Tomography","68Ga-HA-DOTATATE","2025-05-12",{"date":89,"type":90},"2025-05-14","ACTUAL",{"date":92,"type":90},"2020-03-05",{"date":94,"type":75},"2046-08",{"name":5,"class":6},1]